Additionally, among patients over 50 years of age, the incidence of T2 and Gd-enhancing lesions decreased, suggesting that disease activity and the contribution of DMD to relapse suppression are reduced in elderly patients with MS. This evidence concerns the gene DMD and myeloid sarcoma.